PharmaRadar360

PharmaRadar360

🇨🇦·1d agoRegulatory

TZIELD (teplizumab) and the Risk of Viral Reactivation

Serious and life-threatening cases of viral reactivation, including Epstein–Barr virus (EBV) and cyt...

Publisher

H
Health Canada Recalls and Safety Alerts

Canada

This page provides a limited summary, publisher metadata, and related coverage to support discovery before sending readers to the original article.

Read original

At a glance

Publisher
Health Canada Recalls and Safety Alerts
Region
Canada
Scope
Regulatory
Published
September 14, 2026
Language
EN

Topics

OGL-Canada-2.0

Publisher context, original article off-platform

This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.

Summary excerpt

Serious and life-threatening cases of viral reactivation, including Epstein–Barr virus (EBV) and cyt...

Source route

Continue on recalls-rappels.canada.ca

Leave the platform to read the original full article on the publisher site.

Source: Health Canada Recalls and Safety Alerts

Scope: Regulatory

Open original article
TZIELD (teplizumab) and the Risk of Viral Reactivation | PharmaRadar360